Stimulation of plasminogen activation by recombinant cellular prion protein is conserved in the NH₂-terminal fragment PrP23-110

Summary

Keywords

Cellular prion protein (PrP^c) - tissue-type plasminogen activator (t-PA) - plasminogen - central nervous system

• References

• 1 Collen D, Lijnen HR.. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-24.
• 2 Nagase H.. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997; 378: 151-60.
• 3 Wiman B, Collen D.. Molecular mechanism of physiological fibrinolysis. Nature 1978; 272: 549-50.
• 4 Blasi F.. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 1993; 15: 105-11.
• 5 Hayden SM, Seeds NW.. Modulated expression of plasminogen activator system components in cultured cells from dissociated mouse dorsal root ganglia. J Neurosci 1996; 16: 2307-17.
• 6 Seeds NW, Williams BL, Bickford PC.. Tissue plasminogen activator induction in Purkinje neurons after cerebellar motor learning. Science 1995; 270: 1992-4.
• 7 Madani R, Hulo S, Toni N, Madani H, Steimer T, Muller D.. et al. Enhanced hippocampal long-term potentiation and learning by increased neuronal expression of tissue-type plasminogen activator in transgenic mice. Embo J 1999; 18: 3007-12.
• 8 Muller CM, Griesinger CB.. Tissue plasminogen activator mediates reverse occlusion plasticity in visual cortex. Nat Neurosci 1998; 1: 47-53.
• 9 Chen ZL, Strickland S.. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 1997; 91: 917-25.
• 10 Ledesma MD, Da Silva JS, Crassaerts K, Delacourte A, De Strooper B, Dotti CG.. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. EMBO Rep 2000; 1: 530-5.
• 11 Kingston IB, Castro MJ, Anderson S.. In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid beta-peptide analogues. Nat Med 1995; 1: 138-42.
• 12 Dormont D.. Prion diseases: pathogenesis and public health concerns. FEBS Lett 2002; 29: 17-21.
• 13 Van Rheede T, Smolenaars MM, Madsen O, De Jong WW.. Molecular evolution of the Mammalian prion protein. Mol Biol Evol 2003; 20: 111-21.
• 14 Rieger R, Edenhofer F, Lasmezas CI, Weiss S.. The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells. Nat Med 1997; 3: 1383-8.
• 15 Bonomo RP, Imperllizzeri G, Pappalardo G, Rizzarelli E, Tabbi G.. Copper(II) binding modes in the prion octapeptide PHGGGWGQ: a spectroscopic and voltammetric study. Chemistry 2000; 6: 4195-202.
• 16 Fischer MB, Roeckl C, Parizek P, Schwarz HP, Aguzzi A.. Binding of disease-associated prion protein to plasminogen. Nature 2000; 408: 479-83.
• 17 Ellis V, Daniels M, Misra R, Brown DR.. Plasminogen activation is stimulated by prion protein and regulated in a copper-dependent manner. Biochemistry 2002; 41: 6891-6.
• 18 Laemmli UK.. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
• 19 Schagger H, von Jagow G.. Blue native electrophoresis for isolation of membrane protein complexes in enzymatically active form. Anal Biochem 1991; 199: 223-31.
• 20 Jackson GS, Hosszu LL, Power A, Hill AF, Kenney J, Saibil H.. et al. Reversible conversion of monomeric human prion protein between native and fibrilogenic conformations. Science 1999; 283: 1935-7.
• 21 Brimacombe DB, Bennett AD, Wusteman FS, Gill AC, Dann JC, Bostock CJ.. Characterization and polyanion-binding properties of purified recombinant prion protein. Biochem J 1999; 342: 605-13.
• 22 Warner RG, Hundt C, Weiss S, Turnbull JE.. Identification of the heparan sulfate binding sites in the cellular prion protein. J Biol Chem 2002; 277: 18421-30.
• 23 Loscalzo J.. Structural and kinetic comparison of recombinant human single- and two-chain tissue plasminogen activator. J Clin Invest 1988; 82: 1391-7.
• 24 Calabresi P, Napolitano M, Centonze D, Marfia GA, Gubellini P, Teule MA.. et al. Tissue plasminogen activator controls multiple forms of synaptic plasticity and memory. Eur J Neurosci 2000; 12: 1002-12.
• 25 Qian Z, Gilbert ME, Colicos MA, Kandel ER, Kuhl D.. Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature 1993; 361: 453-7.
• 26 Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET.. et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001; 7: 59-64.
• 27 Rogove AD, Siao C, Keyt B, Strickland S, Tsirka SE.. Activation of microglia reveals a non-proteolytic cytokine function for tissue plasminogen activator in the central nervous system. J Cell Sci 1999; 112: 4007-16.
• 28 Bandtlow CE, Zimmermann DR.. Proteoglycans in the developing brain: new conceptual insights for old proteins. Physiol Rev 2000; 80: 1267-90.
• 29 Harris DA, Huber MT, van Dijken P, Shyng SL, Chait BT, Wang R.. Processing of a cellular prion protein: identification of N- and C-terminal cleavage sites. Biochemistry 1993; 32: 1009-16.
• 30 Chen SG, Teplow DB, Parchi P, Teller JK, Gambetti P, Autilio-Gambetti L.. Truncated Forms of the Human Prion Protein in Normal Brain and in Prion Diseases. J Biol Chem 1995; 270: 19173-80.
• 31 Bok RA, Mangel WF.. Quantitative characterization of the binding of plasminogen to intact fibrin clots, lysine-sepharose, and fibrin cleaved by plasmin. Biochemistry 1985; 24: 3270-86.
• 32 Tagliavini F, Prelli F, Verga L, Giaccone G, Sarma R, Gorevic P.. et al. Synthetic peptides homologous to prion protein residues 106-147 form amyloid-like fibrils in vitro. Proc Natl Acad Sci U S A 1993; 90: 9678-82.
• 33 Mishra RS, Gu Y, Bose S, Verghese S, Kalepu S, Singh N.. Cell surface accumulation of a truncated transmembrane prion protein in GSS P102L. J Biol Chem 2002: 24554-61.
• 34 Hsiao K, Groth D, Scott M, Yang S, Serban H, Rapp D.. et al. Serial transmission in rodents of neurodegeneration from transgenic mice expressing mutant prion protein. PNAS 1994; 91: 9126-30.